EyePoint, Inc. Common Stock

EYPT

Market cap $1.36B

16.40 USD

+0.41

2.56%

At close Updated Dec 15, 4:00 PM EST

Pre-market

After hours

16.50

+0.10

0.61%

1 day

2.56%

5 days

-6.71%

1 month

24.81%

3 months

22.3%

6 months

84.27%

Year to date

104.23%

1 year

115.51%

5 years

241.67%

10 years

-53.28%

About: EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 144

Healthcare Biotechnology